Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies
暂无分享,去创建一个
L. Dupré | L. Obéric | L. Ysebaert | F. Despas | M. White-Koning | A. Quillet-Mary | E. Chatelut | F. Thomas | F. Gallais | B. Allal | S. Barros | C. Protin
[1] Xuelin Huang,et al. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. , 2018, Blood.
[2] C. Nabhan,et al. Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced‐dose ibrutinib: results from a multi‐centre study , 2018, British journal of haematology.
[3] A. Gupta,et al. Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status , 2018, Clinical pharmacology and therapeutics.
[4] G. Follows,et al. OUTCOMES OF PATIENTS POST IBRUTINIB TREATMENT FOR RELAPSED/REFRACTORY CLL: A UK AND IRELAND ANALYSIS , 2017 .
[5] J. Schellens,et al. Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients , 2017, Clinical Pharmacokinetics.
[6] V. Gandhi,et al. Decrease in total protein level of Bruton’s tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes , 2016, Leukemia.
[7] N. Chiorazzi,et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia , 2015, Leukemia.
[8] Mitchell R. Smith. Ibrutinib in B lymphoid malignancies , 2015, Expert opinion on pharmacotherapy.
[9] J. Murphy,et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants , 2015, Pharmacology research & perspectives.
[10] L. Leclercq,et al. Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy Men , 2015, Drug Metabolism and Disposition.
[11] J. Beijnen,et al. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen. , 2014, British journal of clinical pharmacology.
[12] Juthamas Sukbuntherng,et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.
[13] J. Byrd,et al. The B-cell receptor signaling pathway as a therapeutic target in CLL. , 2012, Blood.
[14] C. Geest,et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. , 2012, Blood.
[15] N. Chiorazzi,et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. , 2012, Blood.
[16] France Mentré,et al. Development of a Complex Parent-Metabolite Joint Population Pharmacokinetic Model , 2011, The AAPS Journal.
[17] Douglas H. Thamm,et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.
[18] U. Fuhr,et al. Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers , 2010, Clinical pharmacology and therapeutics.
[19] J. Goldstein,et al. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. , 2005, Pharmacogenomics.
[20] Mats O Karlsson,et al. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. , 2003, British journal of clinical pharmacology.
[21] B. Meibohm,et al. The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients , 2003, Journal of clinical pharmacology.
[22] H. Niiro,et al. Decision making in the immune system: Regulation of B-cell fate by antigen-receptor signals , 2002, Nature Reviews Immunology.
[23] Lewis B. Sheiner,et al. Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[24] Xavier Woot de Trixhe,et al. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies , 2014, Cancer Chemotherapy and Pharmacology.
[25] Anna Tostevin,et al. An observational multi-cohort study on the use and safety of Combivir scored tablets among HIV-infected children and adolescents. Report to the European Medicines Agency (EMA)/ Committee for Medicinal Products for Human Use (CHMP) , 2014 .
[26] V. Haufroid,et al. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. , 2013, Pharmacogenomics.